Eric S. Winer, MD, discusses the efficacy of emavusertib in patients with relapsed/refractory AML harboring FLT3 and/or spliceosome factor mutations.
Eric S. Winer, MD
Advertisement
Eric S. Winer, MD, is clinical director of Adult Leukemia at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School.
Articles by Eric S. Winer, MD
Eric Winer, MD, discusses the rationale for the phase 1/2a TakeAim Leukemia trial of emavusertib in patients with R/R FLT3- and spliceosome-mutated AML.
Eric Stephen Winer, MD, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the FDA approval of ivosidenib in acute myeloid leukemia (AML).
Advertisement
Latest Updated Articles
Dr. Winer Discusses the FDA Approval of Ivosidenib in AMLPublished: May 2nd 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5